title: Risk factors for erythema nodosum leprosum.
abstract: A retrospective study of new borderline lepromatous and lepromatous patients reporting for multidrug therapy (MDT) for leprosy at the Anandaban Leprosy Hospital, Kathmandu, Nepal, over an 8-year period was conducted to determine the prevalence of erythema nodosum leprosum (ENL), the time and frequency of reactions, and clinical and laboratory parameters associated with ENL. An overall prevalence of ENL in this cohort of 19% was found. One third of these reactions occurred in patients before MDT was given, one third in the first 6 months and one third after 6 months of treatment. Nearly 1 in 10 of the ENL reactions occurred in patients who had completed 2 years of MDT; 45% of patients with ENL had more than one episode. Data collected at the patients' first presentation was used to identify four major risk factors. Patients with lepromatous disease, skin infiltration or a bacterial index (BI) of > 4+ were at significantly increased risk. Patients older than 40 were at significantly decreased risk of ENL. There was a linear relationship in the risk of ENL with an increasing BI and an inverse relationship to increasing age. These observations should enable clinicians to recognize patients at first presentation who will be likely to develop ENL.
authors.affiliation: Mycobacterial Research Laboratory, Anandaban Leprosy Hospital, Kathmandu, Nepal.
authors.forename: R
authors.initials: R
authors.lastname: Manandhar
authors.forename: J W
authors.initials: JW
authors.lastname: LeMaster
authors.forename: P W
authors.initials: PW
authors.lastname: Roche
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D002991:Clofazimine / Q000627:therapeutic use; D015331:Cohort Studies; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004893:Erythema Nodosum / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology*; D005260:Female; D006801:Humans; D007917:Leprostatic Agents / Q000627:therapeutic use*; D015440:Leprosy, Lepromatous / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009166:Mycobacterium leprae / Q000472:pathogenicity*; D016017:Odds Ratio; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D014774:Virulence
chemical_list: D007917:Leprostatic Agents; D003622:Dapsone; D002991:Clofazimine